Study Suggests Non-invasive Vagus Nerve Stimulation (nVNS) is effective in accelerating United States Air Force Pilot Training
electroCore, Inc. (Nasdaq: ECOR) announced promising results from an Air Force Research Laboratories (AFRL) study on the effectiveness of non-invasive vagus nerve stimulation (nVNS) in accelerating pilot training. The study, conducted at Wright-Patterson Air Force Base, involved 28 participants from the 711th Human Performance Squadron.
Key findings include:
- Significant positive effect of nVNS over sham on day one (37% after trial one, increasing to 51% after trial 12)
- 99% probability that active nVNS was superior to sham on trial 12
- Higher learning rate in the active nVNS group
The research suggests that electroCore's TAC-STIM (nVNS) technology could potentially enhance sensorimotor learning in USAF Simulator Based Pilot Training, marking a significant advancement in military training techniques.
electroCore, Inc. (Nasdaq: ECOR) ha annunciato risultati promettenti da uno studio dei Laboratori di Ricerca dell'Air Force (AFRL) sull'efficacia della stimolazione nervosa vago non invasiva (nVNS) nell'accelerare l'addestramento dei piloti. Lo studio, condotto presso la base aerea di Wright-Patterson, ha coinvolto 28 partecipanti del 711° Stormo di Prestazioni Umane.
I risultati chiave includono:
- Significativo effetto positivo della nVNS rispetto al trattamento placebo nel primo giorno (37% dopo il primo trial, che aumenta al 51% dopo il dodicesimo trial)
- Probabilità del 99% che la nVNS attiva fosse superiore al placebo nel dodicesimo trial
- Maggiore tasso di apprendimento nel gruppo della nVNS attiva
La ricerca suggerisce che la tecnologia TAC-STIM (nVNS) di electroCore potrebbe potenzialmente migliorare l'apprendimento sensorimotorio nell'addestramento dei piloti basato su simulatori dell'USAF, segnando un avanzamento significativo nelle tecniche di addestramento militare.
electroCore, Inc. (Nasdaq: ECOR) anunció resultados prometedores de un estudio de los Laboratorios de Investigación de la Fuerza Aérea (AFRL) sobre la efectividad de la estimulación no invasiva del nervio vago (nVNS) para acelerar el entrenamiento de pilotos. El estudio, realizado en la Base de la Fuerza Aérea de Wright-Patterson, involucró a 28 participantes del 711.º Escuadrón de Rendimiento Humano.
Los hallazgos clave incluyen:
- Efecto positivo significativo de la nVNS sobre el placebo en el primer día (37% después del primer ensayo, aumentando al 51% después del duodécimo ensayo)
- Probabilidad del 99% de que la nVNS activa fuera superior al placebo en el duodécimo ensayo
- Mayor tasa de aprendizaje en el grupo de nVNS activa
La investigación sugiere que la tecnología TAC-STIM (nVNS) de electroCore podría potencialmente mejorar el aprendizaje sensoromotor en el Entrenamiento de Pilotos Basado en Simuladores de la USAF, marcando un avance significativo en las técnicas de entrenamiento militar.
electroCore, Inc. (Nasdaq: ECOR)는 비침습적 미주신경 자극(nVNS)이 조종사 훈련 가속화에 효과적이라는 공군 연구 실험실(AFRL) 연구 결과를 발표했습니다. 이 연구는 라이트-패터슨 공군 기지에서 수행되었으며, 711 인체 성능 비행단의 28명의 참가자가 포함되었습니다.
주요 발견 사항은 다음과 같습니다:
- 첫날 두드러진 nVNS의 긍정적인 효과(첫 번째 실험 후 37%, 12번째 실험 후 51%로 증가)
- 12번째 시험에서 활성 nVNS가 플라세보보다 우월할 확률 99%
- 활성 nVNS 그룹의 학습 속도 증가
이 연구는 electroCore의 TAC-STIM (nVNS) 기술이 미국 공군 시뮬레이터 기반 조종사 훈련에서 감각운동 학습을 향상시킬 수 있는 가능성을 제시하며, 군사 훈련 기술의 중요한 발전을 의미합니다.
electroCore, Inc. (Nasdaq: ECOR) a annoncé des résultats prometteurs d'une étude des Laboratoires de Recherche de l'Air Force (AFRL) sur l'efficacité de la stimulation non invasive du nerf vague (nVNS) pour accélérer la formation des pilotes. L'étude, réalisée à la base aérienne de Wright-Patterson, a impliqué 28 participants du 711e Escadron de Performance Humaine.
Les principales conclusions incluent :
- Efficacité positive significative de la nVNS par rapport au placebo le premier jour (37% après le premier essai, passant à 51% après le douzième essai)
- Probabilité de 99% que la nVNS active soit supérieure au placebo lors du douzième essai
- Taux d'apprentissage plus élevé dans le groupe nVNS actif
La recherche suggère que la technologie TAC-STIM (nVNS) d'electroCore pourrait potentiellement améliorer l'apprentissage sensorimoteur dans la formation de pilotes de l'USAF basée sur des simulateurs, marquant un progrès significatif dans les techniques de formation militaire.
electroCore, Inc. (Nasdaq: ECOR) kündigte vielversprechende Ergebnisse aus einer Studie der Air Force Research Laboratories (AFRL) zur Wirksamkeit der nicht-invasiven Vagusnervstimulation (nVNS) zur Beschleunigung der Pilotenausbildung an. Die Studie, die an der Wright-Patterson Air Force Base durchgeführt wurde, umfasste 28 Teilnehmer der 711. Human Performance Squadron.
Die wichtigsten Ergebnisse sind:
- Signifikant positiver Effekt der nVNS im Vergleich zur Kontrollgruppe am ersten Tag (37% nach der ersten Prüfung, Steigerung auf 51% nach der zwölften Prüfung)
- 99% Wahrscheinlichkeit, dass die aktive nVNS in der zwölften Prüfung überlegen war
- Höhere Lernrate in der aktiven nVNS-Gruppe
Die Forschung legt nahe, dass die TAC-STIM (nVNS) Technologie von electroCore möglicherweise das sensorimotorische Lernen bei der pilotierten Ausbildung der USAF auf Simulatoren verbessern könnte, was einen bedeutenden Fortschritt in den militärischen Ausbildungstechniken darstellt.
- Study shows significant positive effect of nVNS over sham in pilot training (37-51% improvement)
- 99% probability that active nVNS was superior to sham on trial 12
- Higher learning rate observed in the active nVNS group
- Potential for TAC-STIM to accelerate critical skill learning for military personnel
- Second study in three months showing TAC-STIM's effectiveness in military applications
- None.
Insights
The study on non-invasive Vagus Nerve Stimulation (nVNS) in USAF pilot training presents promising results for accelerating sensorimotor learning. With a
However, it's important to note that this is a small-scale study with only 28 participants. While the results are encouraging, larger trials are needed to confirm the efficacy and safety of nVNS in pilot training. The ongoing evaluation of additional physiological and mechanistic data will be vital in understanding the full impact of this technology on learning rates and performance enhancement in high-stress environments.
The application of nVNS technology in pilot training represents a significant advancement in bioelectronic medicine. By targeting the vagus nerve, this non-invasive approach could potentially enhance cognitive functions critical for complex tasks like flying. The study's protocol, involving two 2-minute stimulations before and during training, suggests a practical and easily implementable method for performance enhancement.
However, we must consider the long-term effects and potential side effects of repeated nVNS use. As this technology progresses, it will be important to develop standardized protocols and ensure the devices meet rigorous safety standards. The success of nVNS in this context could open doors for its application in other high-performance fields, potentially revolutionizing training methods across various industries.
For electroCore (NASDAQ: ECOR), this study represents a potentially significant market opportunity. The positive results in accelerating USAF pilot training could lead to increased adoption of their TAC-STIM technology across military branches. This could translate into substantial government contracts and revenue growth for the company.
However, investors should note that ECOR is still a small-cap stock (
Clinical trial demonstrates the ability of nVNS to accelerate sensorimotor learning in USAF Simulator Based Pilot Training
ROCKAWAY, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the Air Force Research Laboratories (AFRL) presented new results supporting the ability of electroCore’s TAC-STIM (nVNS) to accelerate pilot training. The presentation titled “Accelerating Sensorimotor Learning in A Flight Training Simulation Using Transcutaneous Vagus Nerve Stimulation” was presented on Tuesday, August 26th at the 2024 Medical Health System Research Symposium in Orlando, FL. by Dr. Justin Estepp of the Human Effectiveness Directorate of the United States Air Force Research Laboratories (AFRL). The presentation was based on a study conducted at AFRL’s facilities at Wright-Patterson Air Force Base in Dayton, Ohio. The study was funded by the Department of the Air Force through AFRL.
The study recruited 28 participants from the 711th Human Performance Squadron (nVNS = 14 & Sham = 14). Each subject was assessed on day 0 to establish a baseline. On days 1-4, two 2-minute nVNS stimulation treatments were self-administered by the subject, before and in the middle of daily training. Each participant completed 12 glideslope trials on days 1-4; each simulator trial lasted approximately 2.5 minutes. Performance was measured throughout each trial through the tracking of sensorimotor performance. The study showed a significant positive effect (p<0.05) of nVNS over sham on day one (
“We congratulate the team at AFRL for the cutting-edge research presented in this study,” commented Dan Goldberger, Chief Executive Officer of electroCore. “This is the second study in the past three months to show that TAC-STIM provided a clear improvement in the ability of America’s warfighter to learn a critical skill. We look forward to the additional data from this and other on-going studies designed to identify use cases for TAC-STIM across different branches of our Armed Forces.”
About The Air Force Research Laboratory (AFRL)
The Air Force Research Laboratory is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development, and integration of affordable warfighting technologies for our air, space, and cyberspace force. With a workforce of more than 11,500 across nine technology areas and 40 other operations across the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit: www.afresearchlab.com.
About electroCore, Inc.
electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.
For more information, visit www.electrocore.com.
About TAC-STIM
Proudly made in the USA, TAC-STIM™ is a non-invasive vagus nerve stimulator (nVNS) that utilizes the company’s patented technology to stimulate the vagus nerve. This portable device is designed to work quickly, and enhances human performance by improving memory retention, attention, and mood, accelerating training, and decreasing fatigue. TAC-STIM is a low-risk general wellness product and is not intended to treat or diagnose any medical condition or disease.
For more information, visit www.tac-stim.com.
Forward-Looking Statements
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements regarding the implications of the results from the AFRL study, anticipated results and timing of clinical trials being conducted with TAC-STIM non-invasive vagus nerve stimulation (nVNS), electroCore's business prospects, its sales and marketing and product development plans, future cash flow projections, anticipated costs, its product portfolio or potential markets for its technologies, the availability and impact of payor coverage, the potential of nVNS generally in particular to accelerate training, and other statements that are not historical in nature, particularly those using terminology such as "anticipates," "expects," "believes," "intends," other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to obtain additional financing necessary to continue electroCore's business, sales and marketing and product development plans, the uncertainties inherent in the development of new products or technologies, the ability to successfully commercialize nVNS products, competition in the industry in which electroCore operates and general market conditions. The results of earlier preclinical studies and clinical trials may not be predictive of results of future preclinical studies, clinical trials, or commercial success. All forward-looking statements are made as of the date of this press release, and electroCore undertakes no obligation to update forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should refer to all information set forth in this document and should also refer to the disclosure of risk factors set forth in the reports and other documents electroCore files with the SEC, available at www.sec.gov.
Contact:
ECOR Investor Relations
(973) 302-9253
investors@electrocore.com
FAQ
What is the effect of nVNS on USAF pilot training according to the AFRL study?
How many participants were involved in the ECOR nVNS pilot training study?
What was the probability that active nVNS was superior to sham in the ECOR pilot training study?
How long did each simulator trial last in the ECOR nVNS pilot training study?
